Menu
Not yet recruiting NCT07474870

Outcomes of CTAK Surgery

Phase IV Interventional Keratoconus Corneal Ectasia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Questionnaire and Physical Exam.
Who it may be relevant to
Registry conditions: Keratoconus, Corneal Ectasia. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Outcomes of Corneal Tissue Addition for Keratoplasty (CTAK) in Patients With Ectatic Corneas

Overview

Measuring quality of vision and quality of life outcomes using a validated questionnaire in participants undergoing CTAK surgery for corneal ectasia

Detailed description

The investigators are measuring self-reported quality of vision and quality of life outcomes in participants undergoing CTAK surgery for corneal ectasia

Interventions

  • Behavioral Questionnaire and Physical Exam
    Patient reported outcomes of CTAK surgery

Primary outcome measures

  • Questionnaire [Time frame: One year]

Eligibility criteria

Inclusion criteria

  • Corneal Ectasia and Keratoconus

Exclusion criteria

  • Excessively thin cornea
  • Significant corneal scarring

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

United States · 1 center
  • Byers Eye Institute at Stanford — Palo Alto

Identifiers

NCT: NCT07474870 · 78779

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗